New study analyzes best donor match for AML stem cell transplants
NCT ID NCT07155382
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at 98 adults with acute myeloid leukemia (AML) in first remission who received a stem cell transplant from a matched sibling, matched unrelated, or half-matched family donor. All patients got the same chemotherapy conditioning before transplant. Researchers tracked engraftment, graft-versus-host disease, infections, leukemia relapse, and survival to see how donor type and other factors influenced outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
busulfan, fludarabine, antithymocyte globulin
What this could lead to
If successful, this study could help doctors choose the best donor type and conditioning regimen for AML patients needing a stem cell transplant.
What could go wrong
This is an observational study, not a test of a new treatment. It cannot prove what works best, only suggest patterns. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea